ArticleLife science alliance2021
Urinary prostaglandin E2 as a biomarker for recurrent UTI in postmenopausal women.
Article in Life science alliance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 19 citations in OpenAlex.
- Clinical Characteristics, Microbiological Spectrum, Biomarkers, and Imaging Insights in Acute Pyelonephritis and Its Complicated Forms-A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- A Systematic Review of the (Un)known Host Immune Response Biomarkers for Predicting Recurrence of Urinary Tract Infection.Frontiers in medicine · 2022Pooled it
- More than an infection: the ecological puzzle of recurrent urinary tract infections.Frontiers in cellular and infection microbiology · 2026Review
- CAUTIon - not all UTIs are the same.Nature reviews. Urology · 2025Review
- Urinary biochemical ecology reveals microbiome-metabolite interactions and metabolic markers of recurrent urinary tract infection.NPJ biofilms and microbiomes · 2025Article
- USENSE: A proof-of-concept self-screening tool for home-based recurrent urinary tract infection management.Bioengineering & translational medicine · 2025Article
- Bladder wall-embedded bacteria associated with increased risk of recurrence after electrofulguration in women with antibiotic-recalcitrant urinary tract infection.JU open plus · 2025Article
- Urinary tract infections: pathogenesis, host susceptibility and emerging therapeutics.Nature reviews. Microbiology · 2025Review
- Innovative Biosensor Technologies in the Diagnosis of Urinary Tract Infections: A Comprehensive Literature Review.Indian journal of microbiology · 2024Review
- Inflammatory markers for improved recurrent UTI diagnosis in postmenopausal women.Life science alliance · 2024Article
- Comprehensive insights into UTIs: from pathophysiology to precision diagnosis and management.Frontiers in cellular and infection microbiology · 2024Review
- Urinary Glycosaminoglycans Are Associated with Recurrent UTI and Urobiome Ecology in Postmenopausal Women.ACS infectious diseases · 2023Article
- Prostanoid Metabolites as Biomarkers in Human Disease.Metabolites · 2022Review
- Pathophysiology and potential treatment modalities in women with recurrent urinary tract infection.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urinary tract infection (UTI) is one of the most common adult bacterial infections and exhibits high recurrence rates, especially in postmenopausal women. Studies in mouse models suggest that cyclooxygenase-2 (COX-2)-mediated inflammation sensitizes the bladder to recurrent UTI (rUTI). However, COX-2-mediated inflammation has not been robustly studied in human rUTI. We used human cohorts to assess urothelial COX-2 production and evaluate its product, PGE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.